Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

4 reports from 4 outlets in 1 language · first reported 2026-09-30 05:00 UTC · updated 2026-09-30 05:22 UTC · JSON

Reports

1. F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosisfinanznachrichten.de · en · 2026-09-30 05:22 UTC
2. Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosismanilatimes.net · en · 2026-09-30 05:12 UTC
3. Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosistimesargus.com · en · 2026-09-30 05:00 UTC
4. Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosisGlobeNewswire — all · en · 2026-09-30 05:00 UTC